Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc > split?

<< Previous

Bullboard Posts

Next >>

Comment by WTStockon Feb 28, 2021 10:48pm

270 Views

Post# 32683209

RE:RE:RE:RE:RE:RE:RE:RE:RE:split?

Split be the worst thing for us right now specially for the people that have been in the stock for a couple years now.

if people are not buying at this price range and moving the stock price up what makes you think they're going to buy in on a split and spend 1 to 2 to 3 dollars a share if they're not even willing to spend $.05, $.08 even $.10 a share

500,000 shares at nine cents I'd rather keep that and have the price go up to $.65 or even a dollar I split would horrible for a lot of people in the same situation as me.

<< Previous

Bullboard Posts

Next >>

BlackBerry: 600,000 cyberattacks on critical infrastructure in Q3 2024